AbbVie 2012 Annual Report Download - page 143

SUMMARY COMPENSATION TABLE
Each of AbbVie’s named executive officers was employed by Abbott prior to the Separation;
therefore, the information provided for the years 2012, 2011 and 2010 reflects compensation earned at
Abbott and the design and objectives of the Abbott executive compensation programs in place prior to
the Separation. Each of AbbVie’s 2012 named executive officers was, as of December 31, 2012, an
officer of Abbott. Accordingly, the compensation decisions regarding AbbVie’s named executive officers
were made by the Abbott Compensation Committee or its delegates. Executive compensation decisions
following the Separation will be made by AbbVie’s Compensation Committee. All references in the
following tables to stock options, restricted stock units and restricted stock relate to awards granted by
Abbott in respect of Abbott common shares. Pursuant to the Employee Matters Agreement dated
December 31, 2012 by and between AbbVie and Abbott, these equity awards, other than performance-
based restricted shares granted to named executive officers on December 1, 2012, have been converted
into awards in respect of AbbVie common stock and awards in respect of Abbott common shares
reflecting the respective post-Separation values of AbbVie and Abbott. The performance-based
restricted shares granted to named executive officers on December 1, 2012 were converted entirely into
performance-based awards of restricted AbbVie common stock.
The following table summarizes compensation awarded to, earned by, or paid to AbbVie’s named
executive officers in connection with their service to Abbott. Position titles refer to each named
executive officer’s title at Abbott in 2012. The section of the proxy statement captioned ‘‘Compensation
Discussion and Analysis—Compensation Philosophy and Components of Pay’’ describes in greater
detail the information reported in this table.
Change in
Pension
Value and
Non-Equity Non-qualified
Incentive Deferred
Stock Option Plan Compensation All Other
Salary Bonus Awards Awards Compensation Earnings Compensation Total
Name and Principal Position Year ($) ($) ($)(1) ($)(2)(3) ($)(4) ($)(5) ($)(6) ($)
Richard A. Gonzalez ..... 2012 $863,942 $ 0 $3,341,844 $729,640 $2,500,000 $ 64,503 $449,288 $ 7,949,217
Executive Vice President, 2011 825,000 0 1,826,132 343,273 1,230,000 882,988 445,446 5,552,839
Pharmaceutical Products 2010 742,080 300,000(7) 5,135,240 0 848,900 312,256 262,033 7,600,509
Group
Laura J. Schumacher ..... 2012 831,682 1,100,000(8) 4,486,690 576,809 1,270,000 1,771,306 156,261 10,192,748
Executive Vice President, 2011 827,500 0 1,905,327 358,225 1,180,000 1,138,123 158,318 5,567,493
General Counsel, and 2010 823,329 0 3,901,126 535,920 1,100,000 628,869 137,957 7,127,201
Corporate Secretary
William J. Chase ....... 2012 398,942 500,000(8) 2,113,216 162,079 500,000 498,991 45,689 4,218,917
Vice President, Licensing 2011 375,000 0 628,898 118,370 330,000 316,489 50,734 1,819,491
and Acquisitions
Carlos Alban .......... 2012 615,769 300,000(8) 2,702,141 331,473 675,000 1,801,009 104,278 6,529,670
Senior Vice President, 2011 602,471 0 1,514,013 285,334 610,000 774,355 106,162 3,892,335
Proprietary
Pharmaceutical Products,
Global Commercial
Operations
John M. Leonard, M.D. . . . 2012 640,163 0 2,229,557 224,400 515,600 1,719,253 149,142 5,478,115
Senior Vice President, 2011 636,500 0 1,034,187 194,376 475,500 1,016,012 141,236 3,497,811
Pharmaceuticals, Research
and Development
(1) In accordance with the Securities and Exchange Commission’s rules, the amounts in this column
represent the aggregate grant date fair value of the awards in accordance with Financial
Accounting Standards Board ASC Topic 718. Abbott determines grant date fair value by
29